

CORRIGENDUM


doi:10.1038/nature22083

Corrigendum: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth, Saeed Eshtad, Sylvain A. Jacques, Cecilia E. Ström, Linda M. Svensson, Niklas Schultz, Thomas Lundbäck, Berglind Osk Einarsdóttir, Aljona Saleh, Camilla Göktürk, Pawel Baranczewski, Richard Svensson, Ronnie P.-A. Berntsson, Robert Gustafsson, Kia Strömberg, Kumar Sanjiv, Marie-Caroline Jacques-Cordonnier, Matthieu Desroses, Anna-Lena Gustavsson, Roger Olofsson, Fredrik Johansson, Evert J. Homan, Olga Loseva, Lars Bräutigam, Lars Johansson, Andreas Höglund, Anna Hagenkort, Therese Pham, Mikael Altun, Fabienne Z. Gaugaz, Svante Vikingsson, Bastiaan Evers, Martin Henriksson, Karl S. A. Vallin, Olov A. Wallner, Lars G. J. Hammarström, Elisee Wiita, Ingrid Almlöf, Christina Kalderén, Hanna Axelsson, Tatjana Djureinovic, Jordi Carreras Puigvert, Maria Häggblad, Fredrik Jeppsson, Ulf Martens, Cecilia Lundin, Bo Lundgren, Ingrid Granelli, Annika Jenmalm Jensen, Per Artursson, Jonas A. Nilsson, Pål Stenmark, Martin Scobie, Ulrika Warpman Berglund & Thomas Helleday

Nature **508**, 215–221 (2014); doi:10.1038/nature13181

In this Article, the structure of compound TH650 (4) in Fig. 4a was drawn incorrectly; the correct structure is shown as Fig. 1 to this Corrigendum. Preparative, spectroscopic and biological data associated with this compound are as reported in the Article, and the error does not influence any of the reported data or interpretations. In addition, two of the short hairpin RNA (shRNA) sequences in the Methods section were incorrect and should read as follows: *MTH1* shRNA



TH650 (4)

Figure 1 | This is the correct chemical structure of TH650 (4) from Fig. 4a.

#2 5'-CGAGTTCTCCTGGGCATGAAA-3'; and *MTH1* shRNA #3 5'-CGACGACAGCTACTGGTTT-3'.

We have since found that the reported pENTR4 vector expressing *OGG1* and *MUTYH* carried a frameshift mutation, and as a result the overexpressed mRNA does not translate into proteins. This was not determined in the original Article, as only mRNA was measured. To evaluate whether the *OGG1* and *MUTYH* proteins affect sensitivity to the *MTH1* inhibitor TH588, we generated a pENTR1A vector and expressed *OGG1* and *MUTYH* in U2OS cells (see Supplementary Fig. 1 to this Corrigendum). We find that the overexpression of *OGG1* and *MUTYH* does not influence sensitivity to TH588 (Supplementary Fig. 1 of this Corrigendum), in line with what was originally reported. Hence, the interpretation of the results is as presented in the original Article.

Finally, we would like to add the following sentence to the end of the current 'Competing financial interests' statement: "The patent covers compound matters and is fully owned by a not-for-profit public foundation, the Helleday Foundation, that supports medical research. There is no reward scheme to inventors." The original Article has not been corrected.

Supplementary Information is available in the online version of the Corrigendum.